Optimind Pharma Corp. Stock OTC Markets
Equities
LOONF
CA68405U1012
Biotechnology & Medical Research
Sales 2022 | 99.69K 72.9K | Sales 2023 | 170K 124K | Capitalization | 3.91M 2.86M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -3M -2.19M | EV / Sales 2022 * | - |
Net cash position 2022 | 1.22M 892K | Net Debt 2023 | 61.19K 44.75K | EV / Sales 2023 | 23.4 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-1.07
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.31% |
1st Jan change | Capi. | |
---|---|---|
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+2.71% | 22.82B | |
-9.95% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |